<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201171</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1613</org_study_id>
    <nct_id>NCT04201171</nct_id>
  </id_info>
  <brief_title>The Impact of Different CSII and CGM Systems on Different Clinical Outcome Variables in Children and Adolescents With Type 1 Diabetes. An Observational Study Form the Norwegian Childhood Diabetes Registry (NCDR)</brief_title>
  <official_title>The Impact of Different CSII and CGM Systems on Metabolic Control and Quality of Life in Children and Adolescents With Type 1 Diabetes. An Observational Study Form the Norwegian Childhood Diabetes Registry (NCDR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Vest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Fonna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the effect of continuous subcutaneous insulin infusion (CSII) and continuous
      glucose monitoring (CGM) on metabolic control, in a large population-based nationwide
      observational study under real life conditions.

      All children and adolescents with type 1 diabetes are investigated,using annual data in 2017
      from the population-based Norwegian Childhood Diabetes Registry (NCDR). HbA1c and incidence
      of diabetes ketoacidosis (DKA) and severe hypoglycemia (SH) are evaluated depending on the
      use of CSII and CGM in a linear mixed-effects and linear regression model adjusted for age,
      biologic gender and diabetes duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Norway, all children with diabetes 0-18 years should, due to a recommendation from the
      national health care authority, receive their diabetes follow-up in a pediatric department.
      All pediatric departments participate in the NCDR reporting standardized clinical data on
      their patients to the NCDR, at diabetes onset and annually, until the patients reach 18 years
      of age. The data completeness of NCDR is high, on individual level 99 % at diabetes onset,
      and 98 % on the annual examinations in 2016 - 2017
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>measured at annual follow-up in 2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DKA</measure>
    <time_frame>registered at annual follow-up in 2017</time_frame>
    <description>diabetic ketoacidosis leading to hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SH</measure>
    <time_frame>registered at annual follow-up in 2017</time_frame>
    <description>Severe hypoglycemia</description>
  </primary_outcome>
  <enrollment type="Actual">2749</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CSII and CGM</intervention_name>
    <description>use of CSII as insulin delivery or CGM as glucose monitoring</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Our cohort consists of 2749 patients with type 1 diabetes, 45.5 % females; mean age was
        12.9 years (SD 3.9, min 1.7, max 20.2) and mean diabetes duration was 5.3 years (SD 3.7)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All registered sybjects with type 1 diabetes in the 2017 annual cohort of the NCDR

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Heiko Bratke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haugesund Hospital, Fonna Health Trust, Norway</affiliation>
  </overall_official>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D</keyword>
  <keyword>CSII</keyword>
  <keyword>CGM</keyword>
  <keyword>diabetic ketoacidosis</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

